

REMARKS

Applicants note that the only rejection in the April 22, 2005 Office Action is the rejection of claims 8-10 under the judicially created doctrine of double patenting over claims 5-7 of U.S. Patent No. 6184380. Applicants have concurrently filed a Terminal Disclaimer with regard to U.S. Patent No. 6184380. Therefore, this ground of rejection is moot and the present application is in condition for allowance. Accordingly, reconsideration and withdrawal of the rejection are respectfully requested.

CONCLUSION

In view of the remarks and the Terminal Disclaimer, further and favorable consideration of all pending claims and the issuance of a Notice of Allowance are respectfully requested.

It is believed that no fee is required for the consideration of this Response. However, if any fees are required, the Commissioner is authorized to charge such fees to our Deposit Account No. 16-1445.

Date: July 21, 2005

lance liu
Lance Y. Liu
Attorney for Applicants
Reg. No. 45,379

Customer No. 28523
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, CT. 06340
(860)686-1652